PDF(Pubmed)
Abstract：
UNASSIGNED: This study compared the secukinumab treatment responses and adverse effects in psoriatic arthritis patients who received secukinumab as second-line with those that received secukinumab after two or more tumor necrosis factor-alpha (TNF-α) inhibitors.
UNASSIGNED: The retrospective study included 68 psoriatic arthritis patients followed up between October 2018 and October 2021. The patients were divided into two groups according to their anti-TNF-α treatment history. Group 1 consisted of 29 patients (11 males, 18 females; mean age: 45.3±13.3 years; range, 21 to 69 years) who had previously received one anti-TNF-α agent, while Group 2 included 39 patients (18 males, 21 females; mean age: 46.4±13.0 years; range, 24 to 70 years) who had been treated with two or more anti-TNF-α agents. Treatment responses of the groups were measured and compared using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Visual Analog Scale (VAS). A posttreatment BASDAI score ≤4 was used as a criterion for remission.
UNASSIGNED: The mean duration of secukinumab treatment was 16.6±12.7 months for Group 1 and 16.0±11.6 months for Group 2 (p=0.84). Both groups responded significantly to secukinumab in terms of BASDAI and VAS scores (p<0.001 and p<0.001, respectively). Group 1 had a greater decline in BASDAI and VAS scores than Group 2 (p=0.045 and p=0.032, respectively). Furthermore, the remission rate was greater in Group 1 compared to Group 2 (58% vs. 34%, p=0.03). The adverse effects of secukinumab treatment were an allergic reaction in Group 1 and one case of ulcerative colitis in Group 2.
UNASSIGNED: Second-line secukinumab treatment resulted in a greater decline in BASDAI and VAS scores. Moreover, secukinumab achieved a significantly higher rate of remission when it was used as second-line therapy after one anti-TNF-α agent.
UNASSIGNED: The retrospective study included 68 psoriatic arthritis patients followed up between October 2018 and October 2021. The patients were divided into two groups according to their anti-TNF-α treatment history. Group 1 consisted of 29 patients (11 males, 18 females; mean age: 45.3±13.3 years; range, 21 to 69 years) who had previously received one anti-TNF-α agent, while Group 2 included 39 patients (18 males, 21 females; mean age: 46.4±13.0 years; range, 24 to 70 years) who had been treated with two or more anti-TNF-α agents. Treatment responses of the groups were measured and compared using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Visual Analog Scale (VAS). A posttreatment BASDAI score ≤4 was used as a criterion for remission.
UNASSIGNED: The mean duration of secukinumab treatment was 16.6±12.7 months for Group 1 and 16.0±11.6 months for Group 2 (p=0.84). Both groups responded significantly to secukinumab in terms of BASDAI and VAS scores (p<0.001 and p<0.001, respectively). Group 1 had a greater decline in BASDAI and VAS scores than Group 2 (p=0.045 and p=0.032, respectively). Furthermore, the remission rate was greater in Group 1 compared to Group 2 (58% vs. 34%, p=0.03). The adverse effects of secukinumab treatment were an allergic reaction in Group 1 and one case of ulcerative colitis in Group 2.
UNASSIGNED: Second-line secukinumab treatment resulted in a greater decline in BASDAI and VAS scores. Moreover, secukinumab achieved a significantly higher rate of remission when it was used as second-line therapy after one anti-TNF-α agent.
摘要：
■这项研究比较了接受苏金单抗作为二线治疗的银屑病关节炎患者的苏金单抗治疗反应和不良反应，以及接受两种或多种肿瘤坏死因子-α（TNF-α）抑制剂后接受苏金单抗的患者。
■回顾性研究包括2018年10月至2021年10月随访的68例银屑病关节炎患者。根据患者抗TNF-α治疗史分为两组。第1组包括29名患者（11名男性，18名女性；平均年龄：45.3±13.3岁；范围，21至69岁）之前曾接受过一种抗TNF-α药物，而第二组包括39名患者(18名男性，21名女性；平均年龄：46.4±13.0岁；范围，24至70岁），曾接受过两种或多种抗TNF-α药物治疗。使用Bath强直性脊柱炎疾病活动指数（BASDAI）和视觉模拟量表（VAS）测量并比较两组的治疗反应。治疗后BASDAI评分≤4被用作缓解的标准。
■苏金单抗治疗的平均持续时间1组为16.6±12.7个月，2组为16.0±11.6个月（p=0.84）。两组在BASDAI和VAS评分方面对苏金单抗均有显著反应(分别为p<0.001和p<0.001)。与第2组相比，第1组的BASDAI和VAS评分下降幅度更大（分别为p=0.045和p=0.032）。此外，与第2组相比，第1组的缓解率更高(58%vs.34%,p=0.03)。苏金单抗治疗的不良反应为第1组的过敏反应和第2组的1例溃疡性结肠炎。
■二线苏金单抗治疗导致BASDAI和VAS评分下降幅度更大。此外，苏金单抗作为一种抗TNF-α药物后的二线治疗方案,其缓解率显著较高.
■回顾性研究包括2018年10月至2021年10月随访的68例银屑病关节炎患者。根据患者抗TNF-α治疗史分为两组。第1组包括29名患者（11名男性，18名女性；平均年龄：45.3±13.3岁；范围，21至69岁）之前曾接受过一种抗TNF-α药物，而第二组包括39名患者(18名男性，21名女性；平均年龄：46.4±13.0岁；范围，24至70岁），曾接受过两种或多种抗TNF-α药物治疗。使用Bath强直性脊柱炎疾病活动指数（BASDAI）和视觉模拟量表（VAS）测量并比较两组的治疗反应。治疗后BASDAI评分≤4被用作缓解的标准。
■苏金单抗治疗的平均持续时间1组为16.6±12.7个月，2组为16.0±11.6个月（p=0.84）。两组在BASDAI和VAS评分方面对苏金单抗均有显著反应(分别为p<0.001和p<0.001)。与第2组相比，第1组的BASDAI和VAS评分下降幅度更大（分别为p=0.045和p=0.032）。此外，与第2组相比，第1组的缓解率更高(58%vs.34%,p=0.03)。苏金单抗治疗的不良反应为第1组的过敏反应和第2组的1例溃疡性结肠炎。
■二线苏金单抗治疗导致BASDAI和VAS评分下降幅度更大。此外，苏金单抗作为一种抗TNF-α药物后的二线治疗方案,其缓解率显著较高.
